Abstract
Several studies found an association between the risk of death for COVID-19 patients and hospital overload during the first pandemic wave. We studied this association across the French departments using 82,467 serological samples and a hierarchical Bayesian model. In high-incidence areas, we hypothesized that hospital overload would increase infection fatality rate (IFR) without increasing infection hospitalization rate (IHR). We found that increasing departmental incidence from 3% to 9% rose IFR from 0.42% to 1.14%, and IHR from 1.66% to 3.61%. An increase in incidence from 6% to 12% in people under 60 was associated with an increase in the proportion of people over 60 among those infected, from 11.6% to 17.4%. Higher incidence did increase the risk of death for infected persons, probably due to an older infected population in high-incidence areas rather than hospital overload.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study ANR (Agence Nationale de la Recherche, #ANR-20-COVI-000, #ANR-10-COHO-06), Fondation pour la Recherche Medicale (#20RR052-00), Inserm (Institut National de la Sante et de la Recherche Medicale, #C20-26). The sponsor and funders facilitated data acquisition but did not participate in the study design, analysis, interpretation or drafting. Cohorts funding The CONSTANCES Cohort Study is supported by the Caisse Nationale d Assurance Maladie (CNAM), the French Ministry of Health, the Ministry of Research, the Institut national de la sante et de la recherche medicale. CONSTANCES benefits from a grant from the French National Research Agency [Grant Number ANR-11-INBS-0002] and is also partly funded by MSD, AstraZeneca, Lundbeck and L Oreal. The E3N-E4N cohort is supported by the following institutions: Ministere de l Enseignement Superieur, de la Recherche et de l Innovation, INSERM, University Paris-Saclay, Gustave Roussy, the MGEN, and the French League Against Cancer. The NutriNet-Sante study is supported by the following public institutions: Ministere de la Sante, Sante Publique France, Institut National de la Sante et de la Recherche Medicale (INSERM), Institut National de la Recherche Agronomique (INRAE), Conservatoire National des Arts et Metiers (CNAM) and Sorbonne Paris Nord. The CEPH-Biobank is supported by the Ministere de l Enseignement Superieur, de la Recherche et de l Innovation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval and written or electronic informed consent were obtained from each participant before enrollment in the original cohort. The SAPRIS-SERO study was approved by the Sud-Mediterranee III ethics committee (approval 20.04.22.74247) and electronic informed consent was obtained from all participants for dried blood spot testing. The study was registered (#NCT04392388). All methods were performed in accordance with the relevant guidelines and regulations.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
In regard to data availability, data from the study are protected under the protection of health data regulation set by the French National Commission on Informatics and Liberty (Commission Nationale de l Informatique et des Libertes, CNIL). The data can be made available upon reasonable request to F.C. (fabrice.carrat{at}iplesp.upmc.fr), after a consultation with the steering committee of the SAPRIS-SERO study. The French law forbids us to provide free access to SAPRIS-SERO data; access could however be given by the steering committee after legal verification of the use of the data. Please, feel free to come back to us should you have any additional question.
